Depression in type 1 diabetes was associated with high levels of circulating galectin-3
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective: Neuroinflammatory responses are implicated in depression. The aim was to explore whether depression in patients with type 1 diabetes (T1D) was associated with high circulating galectin-3, controlling for metabolic variables, s-creatinine, life style factors, medication and cardiovascular complications. Design: Cross-sectional. Methods: Participants were T1D patients ( n = 283, 56% men, age 18–59 years, diabetes duration ≥1 year). Depression was assessed by Hospital Anxiety and Depression Scale-depression subscale. Blood samples, anthropometrics and blood pressure were collected, and supplemented with data from medical records and the Swedish National Diabetes Registry. Galectin-3 ≥2.562 µg/l, corresponding to the 85th percentile, was defined as high galectin-3. Results: Median (quartile 1 , quartile 3 ) galectin-3 (µg/l) was 1.3 (0.8, 2.9) for the 30 depressed patients, and 0.9 (0.5, 1.6) for the 253 non-depressed, P = 0.009. Depression was associated with high galectin-3 in all the 283 patients (adjusted odds ratio (AOR) 3.5), in the 161 men (AOR 3.4), and in the 122 women (AOR 3.9). HbA1c, s-lipids, s-creatinine, blood pressure, obesity, smoking, physical inactivity, cardiovascular complications and drugs (antihypertensive, lipid lowering, oral antidiabetic drugs and antidepressants) were not associated with high galectin-3. Conclusions: This is the first study to show an association between depression and galectin-3. Depression was the only explored parameter associated with high circulating galectin-3 levels in 283 T1D patients. High galectin-3 levels might contribute to the increased risk for Alzheimer’s disease, cardiovascular and all-cause mortality observed in persons with depression. Potentially, in the future, treatment targeting galactin-3 might improve the prognosis for patients with high galectin-3 levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Glycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
Sharma, U. C., Pokharel, S., van Brakel, T. J., van Berlo, J. H., Cleutjens, J. P. M., Schroen, B., André, S., Crijns, H. J. G. M., Gabius, H. J., Maessen, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147181.65298.4d · Cited by 947
Penninx, B. W., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-129 · Cited by 839
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S., Larson, M. G., & Levy, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.053 · Cited by 589
Depression and All-Cause and Coronary Heart Disease Mortality Among Adults With and Without Diabetes
Egede, L. E., Nietert, P. J., & Zheng, D. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1339 · Cited by 473
Tynan, R. J., Weidenhofer, J., Hinwood, M., Cairns, M. J., Day, T. A., & Walker, F. R. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.12.011 · Cited by 386
Burguillos, M. A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-Quintanilla, A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, M. J., Osman, A. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.012 · Cited by 365
Domenici, E., Willé, D. R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., Brittain, C., Rujescu, D., Giegling, I., Turck, C. W., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009166 · Cited by 347
Bocéréan, C., & Dupret, E. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0354-0 · Cited by 346
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Galectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and -9
Ochieng, J., Fridman, R., Nangia-Makker, P., Kleiner, D. E., Liotta, L. A., Stetler-Stevenson, W. G., & Raz, A. (1994) · Biochemistry · doi:10.1021/bi00251a020 · Cited by 265
Matrix Metalloproteinase-9 Controls NMDA Receptor Surface Diffusion through Integrin β1 Signaling
Michaluk, P., Mikasova, L., Groc, L., Frischknecht, R., Choquet, D., & Kaczmarek, L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5346-08.2009 · Cited by 206
Weigert, J., Neumeier, M., Wanninger, J., Bauer, S., Farkas, S., Scherer, M. N., Schnitzbauer, A., Schäffler, A., Aslanidis, C., Schölmerich, J., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1619 · Cited by 198
Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link
Korczak, D. J., Pereira, S., Koulajian, K., Matejcek, A., & Giacca, A. (2011) · Diabetologia · doi:10.1007/s00125-011-2240-3 · Cited by 181
Niciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161
Yip, P. K., Carrillo-Jimenez, A., King, P., Vilalta, A., Nomura, K., Chau, C. C., Egerton, A. M. S., Liu, Z.-H., Shetty, A. J., Tremoleda, J. L., et al. (2017) · Scientific Reports · doi:10.1038/srep41689 · Cited by 138
Nio‐Kobayashi, J. (2016) · Anatomical Science International · doi:10.1007/s12565-016-0366-6 · Cited by 112
Role of galectin-3 as a receptor for advanced glycosylation end products
Pricci, F., Leto, G., Amadio, L., Iacobini, C., Romeo, G. R., Cordone, S., Gradini, R., Barsotti, P., Liu, F., Mario, U. D., et al. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07706.x · Cited by 104
Hrynchyshyn, N., Patrick Jourdain, M., Desnos, M., Diébold, B., & Funck, F. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.06.054 · Cited by 102
Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer's Disease
Wang, X., Zhang, S., Lin, F., Chu, W., & Yue, S. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317513495107 · Cited by 100
Wang, B., An, X., Shi, X., & Zhang, J.-A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0952 · Cited by 100
The pleiotropic effects of galectin-3 in neuroinflammation: A review
Shin, T. (2013) · Acta Histochemica · doi:10.1016/j.acthis.2012.11.010 · Cited by 98
Glycemic and Risk Factor Control in Type 1 Diabetes
Eeg-Olofsson, K., Cederholm, J., Nilsson, P. M., Gudbjörnsdóttir, S., Eliasson, B., & for the Steering Committee of the Swedish National Diabetes Register (2007) · Diabetes Care · doi:10.2337/dc06-1406 · Cited by 94
RYBAKOWSKI, J. K., Remlinger-Molenda, A., Czech-Kucharska, A., Wójcicka, M., Michalak, M., & Losy, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.019 · Cited by 91
Imran, T. F., Shin, H. J., Mathenge, N., Wang, F., Kim, B., Joseph, J., Gaziano, J. M., & Djoussé, L. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.09.019 · Cited by 84
Melin, E. O., Thunander, M., Svensson, R., Landin-Olsson, M., & Thulesius, H. O. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0137 · Cited by 80
Self-citationMizoguchi, H., Yamada, K., & Nabeshima, T. (2011) · Biochemistry Research International · doi:10.1155/2011/681385 · Cited by 58
Dange, M. C., Agarwal, A. K., & Kalraiya, R. D. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2367-5 · Cited by 44
Melin, E. O., Thunander, M., Landin‐Olsson, M., Hillman, M., & Thulesius, H. O. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-75 · Cited by 38
Self-citationGalectins testing: New promises for the diagnosis and risk stratification of chronic diseases?
Gruson, D., & Ko, G. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.04.009 · Cited by 35
Ma, Y., Balasubramanian, R., Pagoto, S. L., Schneider, K. L., Hébert, J. R., Phillips, L. S., Goveas, J. S., Culver, A. L., Olendzki, B. C., Beck, J., et al. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301394 · Cited by 29
Melin, E. O., Thunander, M., Landin‐Olsson, M., Hillman, M., & Thulesius, H. O. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1495-8 · Cited by 28
Self-citationTanamas, S. K., Permatahati, V., Ng, W. L., Backholer, K., Wolfe, R. S., Shaw, J. E., & Peeters, A. (2016) · BMC Obesity · doi:10.1186/s40608-016-0085-5 · Cited by 23
Melin, E. O., Svensson, R., Thunander, M., Hillman, M., Thulesius, H. O., & Landin‐Olsson, M. (2017) · BMC Obesity · doi:10.1186/s40608-017-0157-1 · Cited by 20
Self-citationMelin, E. O., Svensson, R., Gustavsson, S.-Å., Winberg, A., Olah, E. D., Landin‐Olsson, M., & Thulesius, H. O. (2016) · Trials · doi:10.1186/s13063-016-1347-8 · Cited by 14
Self-citationDeterminants of temporal changes in galectin-3 level in the general population: Data of PREVEND
van der Velde, A. R., Meijers, W. C., van den Heuvel, E. R., Bakker, S. J. L., van Gilst, W. H., van der Harst, P., Hillege, H. L., & de Boer, R. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.241 · Cited by 13
Melin, E. O. (2014) · Lund University Publications (Lund University) · Cited by 5
Self-citation
Research works printed but not linked: 38
- Relations of depressive symptoms and antidepressant use to body mass index and selected biomarkers for diabetes and cardiovascular disease https org, American Journal of Public Health, 34
- 2012, A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia, Brain, Behavior, and Immunity, 26, 469, 10.1016/j.bbi.2011.12.011 · DOI · Paper page
- 2015, Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation, Cell Reports, 10, 1626, 10.1016/j.celrep.2015.02.012 · DOI · Paper page
- 2014, Depression, smoking, physical inactivity and season independently associated with midnight salivary cortisol in type 1 diabetes, BMC Endocrine Disorders, 14, 75, 10.1186/1472-6823-14-75 · DOI
- 2014, Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds, Annual Review of Pharmacology and Toxicology, 54, 119, 10.1146/annurev-pharmtox-011613-135950 · DOI · Paper page
- 2013, Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression, Journal of Affective Disorders, 146, 286, 10.1016/j.jad.2012.07.019 · DOI
- 2016, Affect school and script analysis versus basic body awareness therapy in the treatment of psychological symptoms in patients with diabetes and high HbA1c concentrations: two study protocols for two randomized controlled trials, Trials, 17, 221, 10.1186/s13063-016-1347-8 · DOI
- 2013, Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure, Archives of Cardiovascular Diseases, 106, 541, 10.1016/j.acvd.2013.06.054 · DOI
- 2015, Extracellular galectin-3 induces MMP9 expression by activating p38 MAPK pathway via lysosome-associated membrane protein-1 (LAMP1), Molecular and Cellular Biochemistry, 404, 79, 10.1007/s11010-015-2367-5 · DOI
- 2010, Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections, PLoS ONE, 5, e9166, 10.1371/journal.pone.0009166 · DOI · Paper page
- 2013, Depression, obesity and smoking were independently associated with inadequate glycemic control in patients with type 1 diabetes, European Journal of Endocrinology, 168, 861, 10.1530/eje-13-0137 · DOI · Paper page
- 2017, Depression differed by midnight cortisol secretion, alexithymia and anxiety between diabetes types: a cross sectional comparison, BMC Psychiatry, 17, 335, 10.1186/s12888-017-1495-8 · DOI
- MarioU, Role of galectin as a receptor for advanced glycosylation end products https org, Kidney International, 200058, 10.1046/j.1523-1755.2000.07706.x · DOI
- 2006, Cytokines sing the blues: inflammation and the pathogenesis of depression, Trends in Immunology, 27, 24, 10.1016/j.it.2005.11.006 · DOI · Paper page
- 2017, Gender, alexithymia and physical inactivity associated with abdominal obesity in type 1 diabetes mellitus: a cross sectional study at a secondary care hospital diabetes clinic, BMC Obesity, 4, 21, 10.1186/s40608-017-0157-1 · DOI
- 2014, A validation study of the Hospital Anxiety and Depression Scale (HADS) in a large sample of French employees, BMC Psychiatry, 14, 1
- 1983, The hospital anxiety and depression scale, Acta Psychiatrica Scandinavica, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x · DOI · Paper page
- 1994, Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and-9, Biochemistry, 33, 14109, 10.1021/bi00251a020 · DOI · Paper page
- 2007, Glycemic and risk factor control in type 1 diabetes, Diabetes Care, 30, 496, 10.2337/dc06-1406 · DOI · Paper page
- 2010, Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes, Journal of Clinical Endocrinology and Metabolism, 95, 1404, 10.1210/jc.2009-1619 · DOI · Paper page
- 2016, Determinants of temporal changes in galectin-3 level in the general population: data of PREVEND, International Journal of Cardiology, 222, 385, 10.1016/j.ijcard.2016.07.241 · DOI
- 2005, Depression and all-cause and coronary heart disease mortality among adults with and without diabetes, Diabetes Care, 28, 1339, 10.2337/diacare.28.6.1339 · DOI · Paper page
- 2013, The pleiotropic effects of galectin-3 in neuroinflammation: a review, Acta Histochemica, 115, 407, 10.1016/j.acthis.2012.11.010 · DOI
- 2011, Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link, Diabetologia, 54, 2483, 10.1007/s00125-011-2240-3 · DOI
- 2017, Tissue-and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and disease, Anatomical Science International, 92, 25, 10.1007/s12565-016-0366-6 · DOI
- 2009, Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin β1 signaling, Journal of Neuroscience, 29, 6007, 10.1523/jneurosci.5346-08.2009 · DOI · Paper page
- WangBAnXShiXZhangJ OF DISEASE Suicide risk in patients with diabetes a systematic review and meta - analysis of https org, MANAGEMENT ENDOCRINE European Journal Endocrinology, 2017177, 10.1530/eje-16-0952 · DOI · Paper page
- 2015, Elevated galectin-3 levels in the serum of patients with Alzheimer’s disease, American Journal of Alzheimer’s Disease and Other Dementias, 30, 729, 10.1177/1533317513495107 · DOI · Paper page
- 2014, Glycemic control and excess mortality in type 1 diabetes, New England Journal of Medicine, 371, 1972, 10.1056/nejmoa1408214 · DOI · Paper page
- 2013, Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile, BMC Medicine, 11, 129, 10.1186/1741-7015-11-129 · DOI · Paper page
- 2012, Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?, Clinical Biochemistry, 45, 719, 10.1016/j.clinbiochem.2012.04.009 · DOI
- 2004, Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction, Circulation, 110, 3121, 10.1161/01.cir.0000147181.65298.4d · DOI · Paper page
- 2011, Matrix metalloproteinases contribute to neuronal dysfunction in animal models of drug dependence, Alzheimer’s disease, and epilepsy, Biochemistry Research International, 2011, 681385
- 2017, Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population, American Journal of Cardiology, 119, 57, 10.1016/j.amjcard.2016.09.019 · DOI
- 2014, LDL cholesterol: controversies and future therapeutic directions, Lancet, 384, 607, 10.1016/s0140-6736(14)61009-6 · DOI · Paper page
- 2017, Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration, Scientific Reports, 7, 41689, 10.1038/srep41689 · DOI · Paper page
- 2012, Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community, Journal of the American College of Cardiology, 60, 1249, 10.1016/j.jacc.2012.04.053 · DOI · Paper page
- 2016, Estimating the proportion of metabolic health outcomes attributable to obesity: a cross-sectional exploration of body mass index and waist circumference combinations, BMC Obesity, 3, 4, 10.1186/s40608-016-0085-5 · DOI
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“Observational studies in diabetic and obese patients have found that depression is linked to higher levels of gal-3, inflammatory cytokines, and parallel dysregulation of glucose metabolism (44).”
BackgroundThe cognitive and psychological effects of living with type 1 diabetes: a narrative review
van Duinkerken, E., Snoek, F. J., & de Wit, M. (2019) · Diabetic Medicine · doi:10.1111/dme.14216 · Cited by 197
Rahimian, R., Belliveau, C., Chen, R., & Mechawar, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.871997 · Cited by 85
“Another interesting clinical investigation showed that depression in type 1 diabetes is associated with high levels of circulating Gal-3 (208).”
BackgroundGalectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior
Srejovic, I., Selakovic, D., Jovicic, N., Jakovljević, V., Lukic, M. L., & Rosic, G. (2020) · Biomolecules · doi:10.3390/biom10050798 · Cited by 76
Melin, E. O., Thulesius, H. O., Hillman, M., Svensson, R., Landin‐Olsson, M., & Thunander, M. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1009-4 · Cited by 38
“As inflammatory processes previously have been demonstrated in depression [1, 3, 5, 25], and as HDL-cholesterol levels have recently been shown to decrease with inflammation [14], we plan further exploration of inflammatory markers such as proinflammatory cytokines in patients with T1D and depression [5].”
BackgroundSelf-citation
Metadata
- Authors
- Melin, E. O., Dereke, J., Thunander, M., & Hillman, M.
- Affiliations
- Lund University (SE)
- Corresponding author
- Melin, Eva Olga
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2018-06
- Volume
- 7
- Issue
- 6
- Pages
- 819-828
- ISSN
- 2049-3614 (ISSN-L)
- PMC
- PMC6000756
- OpenAlex
- W2805013969
- Cited by
- 31
- References
- 41
- Citations by year
- 2026: 1 · 2025: 4 · 2023: 2 · 2022: 7 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrine Connections (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Forskningsrådet i Sydöstra Sverige
- Lunds Universitet
- Region Kronoberg
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, type 1 diabetes, galectin-3, circulating biomarkers, neuroinflammation, Alzheimer's disease risk, cardiovascular complications, mortality risk, sex differences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
